Can heated chemotherapy improve ovarian cancer outcomes?
NCT ID NCT02217956
First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time
Summary
This trial is testing a procedure called HIPEC, where a heated chemotherapy drug (cisplatin) is delivered directly into the abdomen after surgery to remove visible cancer. The goal is to find the safest dose that can be used in patients with advanced ovarian, fallopian tube, or peritoneal cancer who have already received initial chemotherapy. The study focuses on measuring side effects and how long patients remain free of cancer progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Cisplatin given as heated chemotherapy directly into the abdomen (HIPEC) after surgery, plus bevacizumab as maintenance therapy
- What this could lead to
- If successful, this could establish a standardized, safe dose of heated intraperitoneal chemotherapy for advanced ovarian cancer, potentially improving disease control after surgery.
- What could go wrong
- This is an early-phase trial with a small number of participants, so the treatment may not prove effective or safe in larger groups. The heated chemotherapy carries risks of toxicity, and the results may not generalize to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Gustave Roussy
Villejuif, Val de Marne, 94805, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can engineered immune cells target a common ovarian cancer protein?
- Experimental pill takes on Hard-to-Treat ovarian cancer
- Targeted drug hunts down cancer cells in advanced bladder cancer trial
- New biologic drug DBC-664 takes aim at Hard-to-Treat cancers
- Radiation boost may Re-Sensitize ovarian cancer to PARP inhibitors
- Engineered immune cells take aim at Mesothelin-Positive tumors